Level C· Early human research exploring benefitsProspective StudyPubMed

Early and Late Responses of Cultured Human Mesenchymal Stem Cells (MSCs) to Cell-free DNA (cfDNA) in Patients With Acute Myocardial Infarction.

Malinovskaya EM., Veiko NN., Ershova ES., Kameneva LV., Konkova MS., Kostyuk SV.

Prospective Study on Cardiovascular Disease, published in Front Biosci (Landmark Ed) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Front Biosci (Landmark Ed) (2025)
Country
Singapore
Reported sample size
—
Source database
PubMed
PMID
40302333
DOI
10.31083/FBL28255

Abstract (original English)

Acute myocardial infarction (AMI) is accompanied by damage to heart tissues and some cell death. Stem cells are localized in the affected area and contribute to tissue repair. Studies have previously shown that the concentration of cell-free DNA (cfDNA) in the blood (ami-cfDNA) increases significantly in patients with AMI, and GC-rich and oxidized DNA fragments accumulate in the composition of ami-cfDNA. As a result, ami-cfDNA exhibits biological activity in vitro against various types of differentiated human cells. Potentially, ami-cfDNA can influence the functional activity and direction of stem cell differentiation. To verify this assumption, we investigated the effect of ami-cfDNA fragments isolated from the blood of patients with AMI on human adipose tissue mesenchymal stem cells (MSCs) in vitro . The MSC line was used and characterized by stem cell surface markers. Ami-cfDNA and control (hc-cfDNA) samples were isolated from the blood plasma of seven AMI patients and ten healthy donors. The early (0.5-3 hours) and late (1-3 weeks) responses of MSCs to cfDNA action were analyzed. The level of reactive oxygen species, the expression level of numerous genes ( NOX4 , NRF2 , BRCA1 , BCL2 , BAX , MYOD1 , MYOG , MYF5 , MRF4 , RUNX2 , SPP1 , OCN , LPL , AP2 ), the level of double-stranded DNA breaks in nuclei, and changes in the spatial organization of the chromatin in the nucleus

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansMesenchymal Stem CellsMyocardial InfarctionCell-Free Nucleic AcidsCell DifferentiationReactive Oxygen SpeciesMaleMiddle AgedFemaleCells, Cultured

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research